Previously, our research group has developed a small molecule inhibitor against Bcl-3 that could directly interfere with Bcl-3-mediated cyclin D1 activity in melanoma resulting in decreased cell proliferation, cell migration, and invasion, as well as decreased tumor growth in vivo [40]. Here, BCL3 is linked to neoplasm.